

FINAL PROGRAM 2011

WIN Worldwide Innovative Networking
in personalized **cancer** medicine

JULY 6th-8th 2011

Palais des Congrès, Paris [France]

Registration online: www.winconsortium.org

3rd WIN SYMPOSIUM

in personalized **cancer** medicine

A significant step forward in patient care

**A forum for open discussion in
which academia and pharma
will be addressing the rapidly
advancing field of personalized
cancer medicine**

Dr. John Mendelsohn, President of the MD Anderson Cancer Center
and Chairman of WIN Consortium

2011: Gateways to efficacy of cancer diagnostics and therapeutics

- > Evidence for efficacy of targeted therapies
- > Improving efficacy of biomarker-driven clinical trials
- > Discovering new targets and predictive biomarkers
- > Combinations of targeted drugs
- > Advances in technology, bioinformatics and systems biology

The scientific content
of this event has
been endorsed by

ASCO

American Society of Clinical Oncology
Making a world of difference in cancer care

ESMO GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

European Society for Medical Oncology

This Symposium has been accredited
with 19 ESMO-MORA category 1 points

EORTC
European Organisation for Research
and Treatment of Cancer

ANRL International Non-Profit Association under Belgian Law 15/20

**INSTITUT
NATIONAL
DU CANCER**

OECE
ORGANISATION OF EUROPEAN CANCER INSTITUTES
EUROPEAN ECONOMIC INTEREST GROUPING




WIN Worldwide Innovative Networking in personalized cancer medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Dear Colleague,

The Worldwide Innovative Networking (WIN) Consortium invites you to attend the third WIN Annual Symposium, dedicated this year to a very challenging topic: Gateways to increasing the efficacy of cancer diagnostics and therapeutics.



The WIN Consortium, initiated by Institut Gustave Roussy (France) and The University of Texas MD Anderson Cancer Center (USA), is a non-profit organization bringing together cancer centers from five continents to address the challenge of increasing the efficacy of global cancer healthcare through personalized therapy. The WIN Consortium aims to foster and facilitate cooperation between cancer centers, pharmaceutical and technology companies, patient advocacy groups, governmental institutions and other stakeholders in the field of early diagnosis and personalized, biomarker-driven treatment of cancer. The goal is to accelerate integration of groundbreaking discoveries into clinical practice in diverse populations, in order to significantly improve clinical outcomes and the quality of life of cancer patients, worldwide. Examples of questions for discussion and debate during WIN3 include:

- Determining the efficacy of targeted cancer therapies
- Determining the efficacy of genetic and molecular biomarkers for selecting patients likely to respond to targeted therapeutics
- Improved design of clinical trials with targeted therapies. Efficient comparisons. Appropriate endpoints. Combinations of therapies. Is randomization necessary?
- Building more effective collaborations between academia, industry and patients.
- Innovation in technologies that identify genetic and molecular abnormalities in cancers.
- Improvements in bioinformatics and applications of systems biology.

We aim to create a forum for open discussion, in which your expertise and input from all stakeholders in cancer drug development are crucial. The WIN Consortium was created to accelerate the pace and reduce the cost of translating effective cancer treatments to the bedside. We need every member and thought leader in the field to be committed and engaged to succeed in our mission.

The 22 founding member institutions of the WIN Consortium invite you to join in this forum, and we invite you and your institution to join the Consortium (<http://www.winconsortium.org>).

JOHN MENDELSON, M.D.

Chairman of WIN Consortium. President of University of Texas MD Anderson Cancer Center



This program has the American Society of Clinical Oncology's approval for quality of educational content. ASCO endorsement does not constitute medical advice. Health care providers should exercise their own independent medical judgement.

What WIN Consortium offers

An opportunity to make an impact on personalized cancer therapy across the globe by increasing the number of patients having access to innovative clinical trials and treatment with the latest innovative drugs

WIN Consortium aims to accelerate the drug development process with:

> **Worldwide basis for innovative biomarker driven clinical trials**

Diversity is the most important asset of WIN, which makes it unique and different from any other initiative. Our patients come from four continents (Asia, North and South America, Europe) plus the Middle East. Each clinical trial will involve a diverse population of patients who share an aberrant genetic function in their tumors, but have different genetic backgrounds and lifestyles that may impact responses to a therapy – a tremendous advantage in early Phase I/II studies.

> **Access to experienced and active laboratory and clinical investigators in prestigious academic oncology centers**

> **Access to high quality, innovative technology platforms**

> **Support and expertise of outstanding technology partners** (currently Agilent Technologies, Life Technologies and GE Healthcare)

> **Simultaneous conduct of trials** in several cancer centers and several countries

> **Continuity of preclinical, phase I, II and III clinical trials up to successful registration**

> **Standardization of procedures:** biobanking, laboratory methods, enrollment of patients, quality assurance, and protocol review

For more information on how to join the WIN Consortium, contact us on

www.winconsortium.org

or at the WIN Secretary Office at vladimir.lazar@igr.fr

WIN Worldwide Innovative Networking in personalized cancer medicine


July 6th-8th, 2011. Palais des Congrès de Paris. France

Academic Institutes and Non-profit Organizations

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre	Mumbai [India]
Ben-Gurion University of the Negev	Beer Sheva [Israel]
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan [Italy]
Fudan University Shanghai Cancer Center	Shanghai [China]
Fundação Pio XII, Hospital de Câncer de Barretos Pius XII Foundation Barretos	Sao Paulo [Brazil]
Fundació Privada Institut d'Investigació Oncològica de Vall Hebron (VHIO)	Barcelona [Spain]
Hadassah University Medical Center	Jerusalem [Israel]
Institut de Cancérologie Gustave Roussy	Villejuif [France]
Institute for Digestive Diseases and Liver Transplantation (ICBDTHF)	Bucharest [Romania]
King Hussein Cancer Center	Amman [Jordan]
National Breast Cancer Foundation	Texas [United States]
National Cancer Centre Singapore	[Singapore]
The Oncology Institute Ion Chiricuta (IOCN)	Cluj-Napoca [Romania]
Sage Bionetworks	Seattle [United States]
Segal Cancer Centre, Jewish General Hospital, McGill University	Montreal [Canada]
Semmelweis University, Faculty of Medicine, 1st Department of Pathology and Experimental Cancer Research	Budapest [Hungary]
Chaim Sheba Medical Center	[Israel]
The University of Medicine and Pharmacy Iuliu Hatieganu	Cluj-Napoca [Romania]
The University of Texas MD Anderson Cancer Center	Houston, Texas [United States]

Associated Technology Partners

Agilent Technologies	California [United States]
General Electric Healthcare	Chalfont St. Giles [United Kingdom]
Life Technologies Corporation	Foster City [United States]



WIN Worldwide Innovative Networking in personalized cancer medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

WIN Consortium Operational Team

WIN Consortium Secretary Office at Institut Gustave Roussy.

114 avenue Edouard Vaillant 94800 Villejuif, France.

Tel: 33 (0) 142 11 40 20 – Email : vladimir.lazar@igr.fr

Chief Operating Officer: Vladimir Lazar

Director of Operational Team: Catherine Bresson

3rd WIN Annual Symposium Organizing Committee

John Mendelsohn, Alexander Eggermont, Richard L. Schilsky, Vladimir Lazar,

Catherine Bresson, Michael Bia

WIN Consortium Leadership

Chairman: John Mendelsohn, The University of Texas MD Anderson Cancer Center

Vice-Chairman: Thomas Tursz, Institut Gustave Roussy

Chairman of the Scientific Advisory Board: Richard L. Schilsky, University of Chicago

Chief Operating Officer: Vladimir Lazar, Institut Gustave Roussy

WIN Consortium Scientific Advisory Board

Chairman: Richard L. Schilsky, University of Chicago

Co-Chairman: Leroy Hood, Institute of Systems Biology

Phillip Febbo	UC-San Francisco
Daniel Hayes	University of Michigan
David Tuveson	Cancer Research UK
Guido Kroemer	INSERM-Institut Gustave Roussy
Laura Van T Veer	Hellen Diller Family CCC, UC-San Francisco
Gary Rosner	Sidney Kimmel Comprehensive Cancer Center John Hopkins
Yves Lussier	University of Chicago
Julio Celis	Danish Cancer Society
Ji Zhang	State Key Laboratory of Medical Genomics/ RuiJIN Sino-French Center of Life Science
Manfred Schmitt	Frauenklinik und Poliklinik der Technischen Universitaet München
Stanley Hamilton	University of Texas MD Anderson
Donald Berry	University of Texas MD Anderson
Manohar Furtado	Life Technologies Corporation
Neil Cook	Agilent Technologies
Ian Wilson	GE Healthcare

WIN Worldwide Innovative Networking in personalized cancer medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Acknowledgements

Our thanks to the laboratories which have helped realize the Worldwide Innovative Networking in Personalized Cancer Medicine Symposium 2011.



GE Healthcare



Bristol-Myers Squibb
Together we can prevail.™



NBCF is a founding member of the WIN Consortium created in 2010. Janelle Hail, founder and CEO of NBCF is a member of the board of directors and the steering committee of the WIN Consortium. The role of NBCF is sharing expertise in organizing structures and fundraising, and organizing educational and prevention efforts worldwide to improve quality of life of cancer patients. WIN Consortium proudly announces in its 3rd WIN Annual Symposium a breakthrough achievement of NBCF: Beyond the Shock educational program. BEYOND THE SHOCK®: Beyond the Shock® is a comprehensive, multi-cultural online guide to understanding breast cancer. Created by the National Breast Cancer Foundation, Inc. (NBCF), it is a resource for women who have been diagnosed with breast cancer, a place for loved ones to gain a better understanding of the disease, and a tool for doctors to share information with their patients. Beyond the Shock® is currently being translated in multiple languages with the mission to bring hope around the world. For more information visit: www.beyondtheshock.com

With thanks to our Media Partners



Program of the **WIN Symposium 2011**

Wednesday, July 6th, 2011

7:30 REGISTRATION

8:15 WELCOME AND OPENING OF THE SYMPOSIUM

ALEXANDER EGGERMONT, DIRECTOR OF INSTITUT GUSTAVE ROUSSY, FRANCE

8:30 KEYNOTE LECTURE

JOHN MENDELSON, CHAIRMAN OF WIN CONSORTIUM AND PRESIDENT OF UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, USA

Challenges and opportunities in personalized cancer therapy and cooperation between the Pharmaceutical Industry and Academia. The WIN Consortium model and operational goals

Session 1: The era of personalized medicine and of significant progress for patient care

Chairmen: Stephen Friend, President Sage Bionetworks, USA.
Nick Botwood, Vice-President Clinical Oncology, AstraZeneca, UK

8:55 MIKE BURGESS, GLOBAL HEAD OF ROCHE PHARMA ONCOLOGY RESEARCH AND EARLY DEVELOPMENT AND LARGE MOLECULE RESEARCH

Dawn of the personalized healthcare era: a significant step forward in patient care

9:20 IAN A. WILSON, HEAD OF BIOLOGY, GE HEALTHCARE MEDICAL DIAGNOSTICS

Molecular Diagnostics and Functional imaging

The three fundamental changes needed to improve current healthcare

9:45 DAVID SIDRANSKY, JOHNS HOPKINS UNIVERSITY, USA

Predict efficacy of therapeutics in day to day clinics: experimental models versus directly exploring tumor molecular portraits

10:10 D. GARY GILLILAND, SENIOR VICE PRESIDENT AND GLOBAL ONCOLOGY FRANCHISE HEAD, MERCK AND CO.

Predicting efficacy of therapeutics in clinical trials: filling the gap between pre-clinical models and phase I clinical trials

WIN Worldwide Innovative Networking in personalized **cancer** medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

10:45 SAMIR HANASH, FRED HUTCHINSON CANCER CENTER, USA
Early diagnostics: a clue for enhanced global efficacy in oncology: Joining WIN Consortium for a global effort to detect lung cancers in earlier stage

11:10-11:30 Coffee Break, network discussions and poster review

Session 2: Challenges of combining targeted therapies

Chairmen: Richard L. Schilsky, Chairman of WIN Scientific Advisory Board, University of Chicago, USA
Fabrice André, Institut Gustave Roussy, France

11:30 ROBERT WASSERMAN, VICE PRESIDENT, PHC STRATEGIC EXPERT OF ROCHE PHARMA ONCOLOGY RESEARCH AND EARLY DEVELOPMENT
Vemurafinib (a BRAF inhibitor) - The thrill of efficacy and the challenge of emerging tumor resistance

11:50 RAZELLE KURZROCK, CHAIR, DEPARTMENT OF INVESTIGATIONAL CANCER THERAPEUTICS-PHASE I PROGRAM, UT-MD ANDERSON CANCER CENTER, USA
Academic perspective: Increasing the predictive value of early phase clinical trials to screen new agents or combinations likely to be efficacious in a defined patient population

12:10 SHANNON MORRIS, DIRECTOR, EARLY DEVELOPMENT UNIT, CANCER RESEARCH, GLAXOSMITHKLINE ONCOLOGY
Pharmaceutical Industry perspective: Increasing the predictive value of early phase clinical trials to screen new agents or combinations likely to be efficacious in a defined patient population

12:30 ROUND TABLE - PANEL OF EXPERTS - FORUM OF OPEN DISCUSSION WITH ATTENDEES
Monotherapies or combined therapeutics? Clinically addressing the complexity of molecular pathways in cancer: How can we develop the most relevant combination beyond individual Pharma/Biotech pipelines: a risk sharing approach for the benefit of the patient

Garry Gilliland, MERCK, Nick Botwood, ASTRAZENECA, Mike Burgess, ROCHE, John Mendelsohn, Chairman of the WIN Consortium, Richard L. Schilsky, Chairman of the SAB of the WIN Consortium, Alexander Eggermont, Director of the Institut Gustave Roussy, Thomas Tursz, Institut Gustave Roussy, France

13:15-14:40 Lunch, network discussions and poster review

13:15-14:40 CONCURRENT WORKSHOPS

Workshop of the WIN Consortium Committee on standardization of biobanking and molecular analyses of biopsies in clinical trials (open to the public)

Organizers: Amir Onn, Chaim Sheba Medical Center, Israel, Stanley Hamilton, UT-MDAnderson

Program of the WIN Symposium 2011

Cancer Center, USA with participation of **Vladimir Lazar**, Institut Gustave Roussy, France, **Gerald Batist**, Segal Cancer Centre, Canada, **Ioana Neagoe**, IOCN, Romania, **Rita Mulherkar**, ACTREC TATA Memorial Hospital, India, **Dingwei Ye**, Fudan University Shanghai Cancer Centre, China

Workshop of the WIN Consortium Committee on audit and compliance in clinical trials (open to the public)

Organizers: Richard L. Schilsky, University of Chicago, Chairman of SAB of WIN Consortium and Soo Khee Chee, National Cancer Centre Singapore with participation of **André Lopes Carvalho**, Hospital De Câncer de Barretos, Brasil, **Salmon Asher**, Sharret Institut of Oncology Hadassah Israel and **Fadawa Ali Attiga**, King Hussein Cancer Center, Jordan, **Gilles Vassal**, Institut Gustave Roussy, France, **Lajos Pusztai**, UT-MD Anderson Cancer USA

Session 3: New biomarker strategies in clinical trials

Biomarkers and their intended uses for treatment decisions and drug development decisions

Chairmen: Samir Hanash, Fred Hutchinson Cancer Center, USA
D. Gary Gilliland, Senior Vice President and Global Oncology Franchise Head, Merck and Co

14:40 DONALD BERRY, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, USA
Using biomarkers prospectively in adaptive trials

15:05 LILLIAN SIU, PRINCESS MARGARET HOSPITAL TORONTO, CANADA
Pharmacogenomic testing - matching patients with targeted drugs

15:30 DOMINIQUE STOPPA-LYONNET, INSTITUT CURIE, FRANCE
Genetic background, susceptibility to cancer, and impact on personalized medicine

15:55 WILLIAM VAINCHENKER, INSERM, INSTITUT GUSTAVE ROUSSY, FRANCE
JAK 2 - from basic concepts to clinical diagnostics and therapeutics applications

16:20 GAIL ECKHARDT, UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, USA
US Academic/Industry collaborations for predictive biomarkers in early clinical development: perspectives of joining WIN Consortium efforts

16:45-17:15 Coffee Break, network discussions and poster review

Session 4: Strategic alliances to fight cancer

Chairmen: John Mendelsohn, Chairman of WIN Consortium, President of UT MD Anderson Cancer Center, USA
Alexander Eggermont, Director of Institut Gustave Roussy, France

17:20 THOMAS TURSZ, INSTITUT GUSTAVE ROUSSY, FRANCE
Personalized Oncology: Challenges for Science, Epidemiology and Public Health, the European Prospective

WIN Worldwide Innovative Networking in personalized **cancer** medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

17:45 DENIS LACOMBE, DIRECTOR, EORTC, BELGIUM

Molecular driven clinical trials: the EORTC Network of Core Institutions (NOCI) and perspectives of interactions with WIN Consortium

**18:10 GILBERT LENOIR, PRESIDENT, FRENCH "LIGUE NATIONALE CONTRE LE CANCER",
FOUNDER, CANCER CAMPUS VILLEJUIF, FRANCE**

Alliance between health experts and society to fight cancer: some french initiatives

18:35 JANELLE AND KEVIN HAIL, NATIONAL BREAST CANCER FOUNDATION, USA

Beyond the shock of cancer disease: Education worldwide, prevention and their impact on improving quality of life of cancer patients

19:00 PETER KAPITEIN, INSPIRE2LIVE, THE NETHERLANDS

A perspective from patient advocacy: The urgent need to translate scientific progress to improve the life of cancer patients

19:30 WELCOME COCKTAIL AT PALAIS DES CONGRÈS

Thursday, July 7th, 2011

7:30 REGISTRATION

Session 5: Discovery and Validation of new targets and biomarkers

Chairmen: Daniel Louvard, Head of Research, Institut Curie, France
Soo Khee Chee, National Cancer Centre, Singapore

**8:30 LEROY HOOD, CO-CHAIRMAN OF WIN SAB, PRESIDENT OF INSTITUTE OF SYSTEMS
BIOLOGY, SEATTLE, USA**

Systems Approaches to Medicine and Cancer

8:55 ROBERT KERBEL, SUNNYBROOK HEALTH SCIENCES CENTER, CANADA

Improving the prospects of preclinical models to predict investigational drug efficacy in the clinic and clinical trials

9:20 STEPHEN FRIEND, SAGE BIONETWORKS, USA

How do we study network perturbations in clinical specimens? How do we select "drivers" of malignancies?

Program of the **WIN Symposium 2011**

9:45 **KENNETH ANDERSON**, DANA FARBER CANCER INSTITUTE, USA
Bench to Bedside Translation of Oncogenomics in Multiple Myeloma

10:10 **GUIDO KROEMER**, INSERM, INSTITUT GUSTAVE ROUSSY, FRANCE
Immune parameters affecting the efficacy of chemotherapeutic regimens.

10:35 **PANEL OF EXPERTS - FORUM OF OPEN DISCUSSION WITH ATTENDEES**
Innovative and informative pre-clinical models and translation to clinic

11:00-11:30 Coffee Break, network discussions and poster review

Session 6: WIN-WIN models: concepts for success

Chairmen: Dingwey Ye, Fudan University Shanghai Cancer Center, China
Amir Onn, Chaim Sheba Medical Center, Israel

11:30 **FABIEN CALVO**, DIRECTOR, FRENCH NATIONAL CANCER INSTITUTE
Personalized Medicine: A nationwide initiative for an equal access to cancer treatment in France

11:50 **MARCO PIEROTTI**, ISTITUTO NAZIONALE DEI TUMORI, ITALY
Academic perspective: how to share ideas, resources and intellectual property? What are the Win-Win models?

12:10 **ANTONELLA ISACCHI**, DIRECTOR KINASE PLATFORM, NERVIANO MEDICAL SCIENCES, ITALY
A successful interaction between Academia and Pharma – The NERVIANO Medical Sciences – and Oncology Network of Lombardy

12:30-14:00 Lunch, network discussions and poster review

12:30-14:00 CONCURRENT WORKSHOPS

Workshop of the WIN Consortium Scientific Committee on the design of clinical trials, data processing and access (open to the public)

Organizers: Razelle Kurzrock, UT MDACC, USA and Jean-Charles Soria, Institut Gustave Roussy, France with participation of Donald Berry, UT MDACC, USA, Soo Khee Che, National Cancer Centre, Singapore, Vladimir Lazar, Chief Operating Officer of WIN Consortium, Stephen Friend, SAGE Bionetworks, USA, Jordi Rodón, VHIO, Spain and exceptional participation of Nick Botwood, ASTRA-ZENECA, Mike Burgess, ROCHE and Garry Gilliland, MERCK, Ignacio I Wistuba, UT-MDAnderson, USA. Eitan Rubin, the Shraga Segal department of Microbiology and Immunology, Faculty of Health

WIN Worldwide Innovative Networking in personalized **cancer** medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Sciences, Ben Gurion University. **The Workshop will present the final results from the Biosy-guided CT scan genomic signature from the BATTLE trial at UT-MDACC, USA.**

Workshop of the WIN Consortium Publicity and Fundraising Task Force (open to the public)

Organizers: Janelle Hail, NBCF, USA and Mark Vossenaar, Agilent Technologies, with participation of John Mendelsohn, Chair of WIN Consortium, Alexander Eggermont, Director Institut Gustave Roussy and exceptional participation of Coen van Veenendaal and Peter Kapitein, Inspire2Live organization

Workshop of the WIN Consortium Committee on membership (not open to the public)

Organizers: Gerald Batist, Segal Cancer Centre, Canada and Robert Dann, GE Healthcare, with participation of Marco Pierotti, Istituto Nazionale Dei Tumori, Italy, Catherine Bresson, Director of operations of WIN Consortium, Angel Porgador, Ben Gurion University of Negev, Israel and Oliver Bogler, UT MD Anderson Cancer Center, USA, Thomas Tursz, Institut Gustave Roussy, France

Session 7: Strategies to improve efficiency of clinical trials

Chairmen: Donald Berry, UT MD Anderson Cancer Center, USA
Mike Burgess, Global Head of ROCHE Pharma Oncology Research and Early Development and Large Molecule Research

14:00 **JEAN-CHARLES SORIA**, HEAD OF EARLY CLINICAL TRIALS AND INNOVATIVE THERAPEUTICS UNIT, INSTITUT GUSTAVE ROUSSY, FRANCE
Challenges in early drug development

14:25 **NICK BOTWOOD**, DEVELOPMENT DIRECTOR LATE ONCOLOGY PORTFOLIO, ASTRAZENECA, UK
Gateways to increased efficacy of drug development: From phase II to successful phase III and registration

14:50 **RICHARD GOLDBERG**, CHIEF OF HEMATOLOGY AND ONCOLOGY, NORTH CAROLINA CANCER HOSPITAL, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, USA
Predicting clinical efficacy: Molecular and radiographic markers as heralds of drug response.

15:15 **FORUM OF OPEN DISCUSSION WITH ATTENDEES**
From random to patient selected clinical trials: How should competing trials be prioritized?
Defining thresholds for improved efficiency in clinical trials?

16:00-16:30 Coffee Break, network discussions and poster review

Program of the **WIN Symposium 2011**

Session 8: Breakthrough concepts and technologies developments

Chairmen: Arturo Galvani, Director Discovery, NERVIANO MEDICAL SCIENCES, Italy
Vladimir Lazar, Chief Operating Officer of WIN Consortium, Institut Gustave Roussy, France

16:30 LEO BONILLA, DIRECTOR FOR LIFE SCIENCE RESEARCH, AGILENT TECHNOLOGIES
Multi-omics Data Integration in Human Disease Research to Develop Pathway-level Biological Insights and Hypotheses for Subsequent Targeted Analysis/Verification

16:55 MARTIN NALEY, HEAD OF MEDICAL NEXT GENERATION SEQUENCING, LIFE TECHNOLOGIES
Medical next generation sequencing: Translational medicine aiming to improve health care efficiency

17:20 DOUGLAS HANAHAN, DIRECTOR, SWISS INSTITUTE FOR EXPERIMENTAL CANCER RESEARCH (ISREC), SCHOOL OF LIFE SCIENCES SWISS FEDERAL INSTITUTE OF TECHNOLOGY LAUSANNE, SWITZERLAND
Integrating mouse models of pancreatic cancers: Cross-filtering to identify new subtypes and predictive pre-clinical trials

17:45 STEPHEN PENNINGTON, SCHOOL OF MEDICINE AND MEDICAL SCIENCE, UCD CONWAY INSTITUTE, UNIVERSITY COLLEGE DUBLIN, IRELAND
Personalized proteomics for cancer - unrealistic promises or true potential?

18:10-18:30 Refreshment break

Conclusion: The urgent need for increased access of patients from diverse populations to innovative clinical trials

Chairmen: John Mendelsohn, Chairman of WIN Consortium, President of UT MD Anderson Cancer Center, USA
Alexander Eggermont, Director of Institut Gustave Roussy, France

18:30 RICHARD L. SCHILSKY, CHAIRMAN OF WIN SCIENTIFIC ADVISORY BOARD, UNIVERSITY OF CHICAGO, USA
Personalized medicine, synthesis of the 3rd WIN annual symposium and perspectives

20:30 GALA DINNER

Pavillon Gabriel, 5 avenue Gabriel, 75008 Paris (www.poteletchabot.com)

WIN Worldwide Innovative Networking in personalized **cancer** medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Friday, July 8th, 2011

8:30-12:30

General Assembly of the WIN Consortium (business meeting, restricted to members and open to non members by request and invitation only)

Chairman: John Mendelsohn, Chairman of WIN Consortium, President of UT MD Anderson Cancer Center, USA

Request for invitations at: WIN Consortium Secretary Office: Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France.
Vladimir Lazar, Chief Operating Officer: e-mail: vladimir.lazar@igr.fr

8:30-12:30

6 meeting rooms will be at your disposal for intervals of 45 minutes. Reservations may be made online at www.mfcongres.com from June 15th.

**THE EXHIBITION AREA AND
MEETING ROOMS WILL BE OPEN
AND AT THE DISPOSAL
OF ALL ATTENDEES UNTIL 12:30**

Practical information

WIN Symposium 2011

Badges

All participants will receive their name badge onsite. This badge cannot be exchanged and must be worn during the sessions.

Bank opening times

Banking hours in Paris are usually from 9 am to 5 pm, Monday to Friday. In the rest of France, banks are usually open from 10 am to 1 pm and from 3 pm to 5 pm, Tuesday to Saturday. Banks often close early on the day before a bank holiday.

Carpark

The Palais des Congrès has an underground carpark with direct access to the Congress centre (Capacity of 1800 spaces). Cost not included in registration fee.

Certificate of attendance

Participating delegates will receive a Certificate of Attendance.

Climate

The weather in Paris in July is usually warm with an average temperature of 25°C during the day.

Currency and foreign exchange

The national currency is EURO. Currency can be exchanged at all bank branches and Post Offices. "Bureaux de change" can also be found in large department stores, railway stations, airports and near tourist attractions.

Please note: although the exchange rate is fixed, commission rates are not. These must be clearly displayed.

Disclaimer

The Organising Committee and MF Congrès cannot accept liability for any injury or loss incurred by participants and/or persons accompanying them, nor for loss of, or damage to, their luggage and/or personal belonging.

Electricity

The power supply is 220 V, 50 Hz. Round European style two-pin plugs are used. Appliances designed to operate on 110/120 V require a voltage converter and a plug adapter.

Language

The official language of the Congress is English.

Local time

The time zone in Paris is GMT +1 hour.

Meals

Coffee/tea are included in the registration fee and will be served daily during the coffee breaks. A lunch box is included in the registration fee.

Smoking policy

Please note that smoking is not permitted in the Congress.

Practical information

WIN Symposium 2011

Travel information

Package information (flight + accommodation) will be available on the website: www.mfcongres.com

From the airport to the Palais des Congrès. An airport shuttle operated by Air France departs from Roissy Charles de Gaulle airport every 12 minutes. The bus stops just outside the Palais des Congrès and opposite the Meridien Etoile hotel. The bus fare from the airport to the city of Paris is around 13 Euros. Local number 82, 73, 43, 244 buses and the Petite Ceinture (PC) also stop at the Congress centre. **On the RER**, take line C and alight at Neuilly-Porte Maillot-Palais des Congrès station **and by Metro**, take Line 1 and alight Porte Maillot station. (www.ratp.com)

Car rental: All the large companies have offices both at the airport and in the city. **Driving information:** Speed limits in France are as follows: on motorways 130 km/h, on other roads 90 km/h, and in all cities and villages 50 km/h.

Venue

The 3rd WIN Symposium will be held at:

Palais des Congrès
2, Place de la Porte Maillot, 75017 Paris, France
Tél: +33 (0)1 40 68 22 22
Fax: +33 (0)1 40 68 27 40

The Palais des Congrès of Paris is situated in Porte Maillot, and is connected to the city centre, as well as to the airports and train stations, by metro and buses. For all the information you may need during your stay in Paris (travel, metro plan, social events, museums etc.), please visit the website: www.paris.fr. The website is very comprehensive and is available in English.

You can contact the Paris Tourist Office at
+ 33 (0) 892 68 31 12. and www.parisinfo.com

Symposium secretary

Worldwide Innovative
Networking in personalized
cancer medicine

8, rue Tronchet
75008 Paris (France)

Tel.: +33 (0)1 40 07 11 21
Fax: +33 (0)1 40 07 10 94
mbia@mfcongres.com

Registration online
www.mfcongres.com

Official Carrier

THE BEST PRICE FOR YOUR
AIR TICKET



Get the best price for your flight with
Air France and KLM Global Meetings.
Valid for travel from 01/07/2011
to 13/07/2011

Event ID Code to keep for
the booking: 11339AF

More details:

www.airfranceklm-globalmeetings.com

TRAIN (SNCF) REDUCTIONS



Up to 20% reduction on full
price return rail tickets
(within France). Reduction
vouchers can be ordered from the meeting
secretary (see registration form) and will
be sent with the confirmation of registration.

WIN Worldwide Innovative Networking in personalized **cancer** medicine

July 6th-8th, 2011. Palais des Congrès de Paris. France

Name	Address	Preferential Symposium Rates	Comments
LE MÉRIDIEN ETOILE **** AT THE CONVENTION CENTER	81 bd Gouvion St Cyr 75017 PARIS Tél: +33 (0)1 40 07 11 21 Fax: +33 (0)1 40 07 10 94 mbia@mfcongres.com	<ul style="list-style-type: none">• Classic room, single or double: 225 €• Breakfast included	<ul style="list-style-type: none">• Reception and business center 24 hours a day.• Wifi in public areas.• Explore our 2 restaurants l'Orénoc and the Jazz Club Lounge.• Enjoy live concerts at the Jazz Club.
HOTEL STAR CHAMPS ELYSEES ***	<i>10 minutes walking distance</i> 18 rue de l'Arc de Triomphe 75017 PARIS Tél: +33 (0)1 43 80 27 69 Fax: +33 (0)1 40 54 94 84 reservation@bwstar.fr	<ul style="list-style-type: none">• Classique single: 145€• Classic double: 160€• Buffet included	<ul style="list-style-type: none">• Non smoking hotel• Free Wifi
HOTEL REGENT'S GARDEN BEST WESTERN PREMIER ****	<i>8 minutes walking distance</i> 6 rue Pierre DEMOURS 75017 PARIS Tél: +33 (0)1 45 74 07 30 Fax: +33 (0)1 40 55 01 42 hotel.regents.garden@wanadoo.fr	<ul style="list-style-type: none">• Classic single/double: 220€• Superior Single/double: 250 €• Buffet included	<ul style="list-style-type: none">• Non smoking and ecolabel adopted approach• Free Wifi, mini bar offered in soft drinks, bath robe, large rooms between 15 to 30 m².